SCHEMBL16020335

SCHEMBL16020335

Cc1cnc(Cl)c(NS(=O)(=O)c2cccc(C(=O)O)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.60
▸ TSHR P16473 1/20 0.60
▸ PTK2B Q14289 1/20 0.60
▸ KMT2A Q03164 3/20 0.53
▸ PIK3CG P48736 4/20 0.52
▸ PIK3CD O00329 3/20 0.52
▸ PIK3CA P42336 2/20 0.52
▸ PIK3CB P42338 2/20 0.52
▸ CASP3 P42574 1/20 0.51
▸ SENP8 Q96LD8 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51
▸ SENP6 Q9GZR1 1/20 0.51
▸ PIK3C3 Q8NEB9 2/20 0.51
▸ PI4KA P42356 1/20 0.51
▸ PI4KB Q9UBF8 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ ACLY P53396 1/20 0.49
▸ SLC40A1 Q9NP59 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ CCR2 P41597 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16020314 0.87 KDM4E (0.55) KDM4ETSHRPTK2BKMT2ACASP3
SCHEMBL24139854 0.85 KDM4E (0.57) KDM4ETSHRPTK2BKMT2APIK3CG
SCHEMBL16017558 0.85 KDM4E (0.57) KDM4ETSHRPTK2BKMT2APIK3CG
SCHEMBL12765132 0.85 PIK3CG (0.70) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL13975439 0.84 ACLY (0.55) KDM4ETSHRPTK2BKMT2APIK3CG
SCHEMBL18136822 0.81 CASP3 (0.49) KDM4ETSHRPTK2BKMT2ACASP3
SCHEMBL15529663 0.77 SLC40A1 (0.50) TSHRKMT2APIK3CGPIK3CDPIK3CA
SCHEMBL7372057 0.77 KDM4E (0.64) KDM4ETSHRPTK2BKMT2ACASP3
SCHEMBL16020319 0.77 MEN1 (0.62) KDM4ETSHRPTK2BKMT2ACASP3
SCHEMBL3662990 0.76 PIK3CA (0.68) PIK3CGPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9808466-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 2017-11-07 — — US disclosed
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2016-10-13 — — US disclosed
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 KDM4E 613/4885TSHR 1618/4885PTK2B 203/4885
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 KDM4E 613/4885TSHR 1618/4885PTK2B 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback